In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Sanofi launches hostile bid for Medivation; potential value of $9.3bn; Pfizer steps in and buys Medivation

Executive Summary

Sanofi has gone public with a $52.50 per share all-cash bid to acquire public biotech Medivation Inc. The offer, which values Medivation at about $9.3bn, was immediately rejected by Medivation's board.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash

Related Companies

Advertisement
UsernamePublicRestriction

Register